Geron Corporation (BIT:1GERN)
Italy · Delayed Price · Currency is EUR | Market Cap | 815.71M +4.7% |
| Revenue (ttm) | 179.05M +24.4% |
| Net Income | -59.18M |
| EPS | -0.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 113.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 1.364 |
| Day's Range | n/a |
| 52-Week Range | 0.938 - 1.624 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Geron
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini... [Read more]
Financial Performance
In 2025, Geron's revenue was $183.88 million, an increase of 138.83% compared to the previous year's $76.99 million. Losses were -$83.50 million, -52.17% less than in 2024.
Financial numbers in USD Financial StatementsNews
Geron Earnings Call Transcript: Q2 2026
Q2 2026 saw 17% year-over-year and 11% sequential net revenue growth, with RYTELO expanding its reach and strong financial discipline maintained. Guidance was raised to the mid to high end of $220M-$240M for 2026, and European commercialization plans are expected by year-end.
Geron Earnings release: Q2 2026
Geron released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Geron Quarterly report: Q2 2026
Geron has published its Q2 2026 quarterly earnings report on August 5, 2026.
Geron reports Q2 EPS (2c), consensus (1c)
Reports Q2 revenue $57.48M, consensus $55.38M. “We are executing a focused strategy to build a leading hematology company, which starts with bringing RYTELO to more eligible patients impacted by LR-MD...
Geron sees FY26 revenue $220M-$240M, consensus $234.22M
The company said, “For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 million to $240 million. Geron (GERN) also expects total…
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected ...
Geron Slides: Corporate presentation
Geron has posted slides in relation to its latest quarterly earnings report, which was published on August 2, 2026.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock op...
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod...
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to ...
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a s...
Geron appoints Chinmaya Rath as chief business officer
Geron (GERN) announced the appointment of Chinmaya Rath as chief business officer. Most recently, he served as head of pharma solutions at Cellworks and chief business officer at GlycoMimetics. Publis...
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies Mr. Rath brings senior leadership experience in business development across a range o...
Geron Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
RYTELO’s adoption is rising, driven by focused education and strategic targeting of community physicians. Real-world data supports its efficacy and safety, while ongoing trials and a strong cash position underpin future growth and expansion in hematology.
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod...
Geron Transcript: AGM 2026
The meeting approved all board proposals, including director elections and incentive plan changes. Updates highlighted progress in clinical trials, organizational restructuring, and plans for ex-U.S. commercialization, with key trial results expected by 2028.
Geron Transcript: Stifel 2026 Targeted Oncology Virtual Forum
RYTELO's commercial rollout is accelerating, with updated NCCN guidelines supporting second-line use and strong uptake in community settings. Real-world and long-term data reinforce efficacy and safety, while financial guidance points to near-term profitability and strategic optionality.
Geron Transcript: Bank of America Global Healthcare Conference 2026
RYTELO continues to gain traction in low-risk MDS, with strong Q1 revenue and expanding use in the second-line setting. Real-world evidence supports clinical trial results, and an interim readout for imetelstat in myelofibrosis is expected later this year.
Geron to present RWE study of RYTELO at EHA Congress
Geron (GERN) Corporation announced that the first real-world evidence study of RYTELO in patients with lower-risk myelodysplastic syndromes will be presented at the European Hematology Association 202...
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population
Geron reports Q1 EPS (1c), consensus (2c)
Reports Q1 revenue $51.84M, consensus $50.59M. “We are encouraged by RYTELO demand and net revenue growth in the first quarter. Our refocused commercial strategy, energized team, and commitment to exe...
Geron Earnings Call Transcript: Q1 2026
Q1 2026 saw 31% year-over-year revenue growth and disciplined expense management, keeping the company on track for its 2026 guidance. U.S. RYTELO demand rose 6% sequentially, with commercial and medical strategies fueling further growth and European expansion plans underway.
Geron Earnings release: Q1 2026
Geron released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Geron Quarterly report: Q1 2026
Geron has published its Q1 2026 quarterly earnings report on May 6, 2026.
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating exp...